唑来膦酸抗肿瘤作用的临床研究进展

Clinical trials progression of anti-cancer effects exerted by zoledronic acid

唑来膦酸是第三代双膦酸盐类药物,主要通过抑制破骨细胞的活性和诱导破骨细胞凋亡来抑制骨吸收,目前用于治疗恶性高钙血症、控制恶性肿瘤骨转移等。多个临床前研究显示唑来膦酸具有明确的抗肿瘤作用。近年来,随着多项临床试验的开展,唑来膦酸潜在的抗肿瘤作用也越来越受到关注。多个临床研究结果表明,唑来膦酸能改善多发性骨髓瘤,乳腺癌、前列腺癌、肺癌等恶性肿瘤治疗的疗效,包括延长患者的总生存时间和无病生存期等。然而,对于唑来膦酸与其他抗肿瘤治疗合用的最佳方案和剂量、持续时间还需要进一步的研究。在此,本文就唑来膦酸抗肿瘤作用的临床研究进展作一综述。

Zoledronic acid,the third generation of nitrogen-containing bisphosphonate,is a potent inhibitor of osteoclastic bone resorption by inhibiting osteoclast activity and inducing osteoclast apoptosis and is currently approved for the treatment of tumor-induced hypercalcemia and the reduction and delay of skeletal complications in advanced bone-related malignancies.Data from preclinical studies of zoledronic acid suggest its definite anti-tumor effect.Recently,as several zoledronic acid related clinical trials are carried out,the anti-tumor effect of zoledronic acid attracts people＇s attention.These clinical trials show that zoledronic acid may improve treatment response of multiple myeloma,breast cancer,prostate cancer and lung cancer including prolonging the disease free survival（DFS） and overall survival（OS）.However,some important questions remain,including optimal dosing,initiation and duration of therapy,to be studied in further investigations.Here,we summarized the potential role of zoledronic acid in cancer treatment.